Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Trial With Longer Liver Elevation Needed For Iclaprim, US FDA Tells Motif Bio

Executive Summary

Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.

Advertisement

Related Content

Motif Plunges As FDA Demands New Iclaprim Study
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel